We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

This study has been terminated.
(Poor enrollment.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00791336
First Posted: November 14, 2008
Last Update Posted: July 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Iowa
Results First Submitted: March 9, 2017  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Nelfinavir

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Nelfinavir Nelfinavir: 1250 mg twice daily starting for approximately 6.5 weeks.

Participant Flow:   Overall Study
    Nelfinavir
STARTED   1 
COMPLETED   1 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Nelfinavir Nelfinavir: 1250 mg twice daily starting for approximately 6.5 weeks.

Baseline Measures
   Nelfinavir 
Overall Participants Analyzed 
[Units: Participants]
 1 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      1 100.0% 
>=65 years      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      1 100.0% 
Male      0   0.0% 
Region of Enrollment 
[Units: Participants]
 
United States   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pathologic Complete Response   [ Time Frame: 30 days ]

2.  Secondary:   Characterization of Overall and Disease-free Survival   [ Time Frame: long-term ]

3.  Secondary:   Safety and Tolerability of the Combined Treatment Regimen   [ Time Frame: 7 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There was only one treated participant. Conclusions cannot be drawn from these data due to limited sampling size.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: John M. Buatti, M.D., Chair, Department of Radiation Oncology
Organization: The University of Iowa
phone: 319-356-2699
e-mail: john-buatti@uiowa.edu



Responsible Party: University of Iowa
ClinicalTrials.gov Identifier: NCT00791336     History of Changes
Other Study ID Numbers: 200802788
First Submitted: November 13, 2008
First Posted: November 14, 2008
Results First Submitted: March 9, 2017
Results First Posted: July 28, 2017
Last Update Posted: July 28, 2017